Clinical Trials Logo

Clinical Trial Summary

Study hypothesis: Prevention programme for melioidosis can reduce incidences of overall hospitalization due to infectious diseases and due to culture-confirmed melioidosis in diabetic population in northeast Thailand This study is a prospective single-blind multicentre stepped wedge cluster randomized controlled behaviour change trial in 9,000 diabetics in Ubon Ratchathani, northeast Thailand.


Clinical Trial Description

Melioidosis is an infectious disease caused by soil-dwelling Gram-negative bacilli Burkholderia pseudomallei. The disease is highly endemic in northeast Thailand. Diabetes mellitus is the major underlying risk factor for melioidosis, occurring in more than 50% of all culture-proven melioidosis patients. The annual incidence of melioidosis in diabetes in northeast Thailand is currently 244 per 100,000, and the overall case fatality rate is about 40%. The number of people dying from melioidosis is now comparable to deaths from tuberculosis, and exceeds those from malaria, diarrheal illnesses and measles combined. Melioidosis is potentially preventable since infection occurs as a direct result of exposure to B. pseudomallei in the environment. Nonetheless, most of Thai people have never heard of melioidosis, there is currently no vaccine for melioidosis, and formal prevention guideline are lacking worldwide. The investigators recently developed new guidelines for the prevention of melioidosis in Thailand; including avoidance of direct contact with soil or environmental water and use of protective gear if contact is necessary, consumption of bottled or boiled water only, and avoidance of direct contact with heavy rain and dust clouds. The investigators aim to conduct a clinical trial to determine effectiveness of the proposed prevention programme of melioidosis. The investigators also predict that the prevention programme of melioidosis will also prevent other common infectious diseases with have similar routes of infection, such as leptospirosis and acute diarrhea. The outcome of the RCT will be crucial evidence for the Ministry of Public Health (MoPH) Thailand for their consideration of policy changes for the prevention of melioidosis countrywide. The funder: Wellcome Trust. Grant reference number: 101103/Z/13/Z Result: Pubmed link: https://pubmed.ncbi.nlm.nih.gov/34170931/ PLoS NTD link: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009060 DOI: https://doi.org/10.1371/journal.pntd.0009060 MedRxiv: https://www.medrxiv.org/content/10.1101/2020.12.18.20248448v1 ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02089152
Study type Interventional
Source University of Oxford
Contact
Status Completed
Phase N/A
Start date April 1, 2014
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Completed NCT04299412 - Diagnostic Accuracy of the DPP II Assay
Recruiting NCT06089668 - An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis
Completed NCT03528265 - Adapting LFI for Melioidosis
Completed NCT05105035 - Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients Phase 2
Completed NCT01766830 - Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) N/A
Recruiting NCT03048513 - Clinical Presentation of Melioidosis in Head and Neck Region N/A
Completed NCT02668406 - Study to Obtain Blood and Voided Urine Samples to Improve the Diagnosis of Melioidosis
Recruiting NCT00579956 - A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis N/A
Completed NCT01420341 - Co-trimoxazole as Maintenance Therapy for Melioidosis Phase 4